SHP 639

Drug Profile

SHP 639

Alternative Names: SHP639

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire
  • Class Eye disorder therapies; Natriuretic agents; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Ocular hypertension

Most Recent Events

  • 10 May 2017 Phase-I clinical trials in Glaucoma in USA (Ophthalmic) (NCT03131167)
  • 10 May 2017 Phase-I clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT03131167)
  • 03 May 2017 Shire files an IND application with the US FDA in USA for Glaucoma and Ocular hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top